title: Home parenteral lipids in AIDS: a three-month study.
abstract: Parenteral nutrition is a part of the nutritional support regimen of patients with AIDS-associated wasting syndrome and gastrointestinal dysfunction. The cholesterol (CHOL) level in human immunodeficiency virus (HIV) membrane is very high, and recent lipid formulations with high phospholipid (PL) content have demonstrated the ability to trap CHOL from endogenous sources, modifying the composition of cell membranes. We administered lipid-based home parenteral nutrition for 3 mo to malnourished AIDS patients. The patients were randomly divided into two groups: 23 received the regular 20% fat emulsion formulation, and 27 received a 2% formulation enriched 10-fold with PLs but containing the same amount of triglycerides. All patients gained weight and improved their activity level. Those receiving the high-PL composition showed increased serum CHOL concentrations (from 147 to 241 mg/dL; P < 0.01), but no increase was seen in the number of CD4 cells or improvement in immune function. HIV infectivity was not modified. Patients receiving regular PLs had significantly decreased (P < 0.02) IgA concentrations (from 776 to 300 mg/dL) and improved mitogen response to phytohemagglutinin and to concanavalin A. This formula, too, had no effect on HIV infectivity. We conclude that standard parenteral nutritional influences the nutritional and immune status of malnourished AIDS patients. A PL-enriched parenteral formulation can trap CHOL, but it does not affect the immune profile or HIV infectivity in patients with advanced disease.
authors.affiliation: General Intensive Care Unit, Beilinson Medical Center, Petah Tiqva, Israel.
authors.forename: P
authors.initials: P
authors.lastname: Singer
authors.forename: R
authors.initials: R
authors.lastname: Levine
authors.forename: M
authors.initials: M
authors.lastname: Rothkopf
authors.forename: J
authors.initials: J
authors.lastname: Askanazi
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D000328:Adult; D018791:CD4 Lymphocyte Count; D002784:Cholesterol / Q000097:blood; D003208:Concanavalin A / Q000494:pharmacology; D005217:Fat Emulsions, Intravenous; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D008875:Middle Aged; D016331:Parenteral Nutrition, Home; D010743:Phospholipids / Q000008:administration & dosage*; D010835:Phytohemagglutinins / Q000494:pharmacology; D011795:Surveys and Questionnaires
chemical_list: D005217:Fat Emulsions, Intravenous; D007070:Immunoglobulin A; D010743:Phospholipids; D010835:Phytohemagglutinins; D003208:Concanavalin A; D002784:Cholesterol